IL6 and myeloid sarcoma: In the same study, oral phycocyanobilin (5 mg/kg) treatment in EAE-C57BL/6 mice improved clinical progression and reduced neuroinflammation by significantly lowering brain expression of IL-6 and IFN-γ, which are pro-inflammatory cytokines implicated in MS pathology [113].